Ariad Pharmaceuticals(NASDAQ:ARIA) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $68.13M. Analysts estimated a revenue of $60.64M. Earnings per share were $-0.06. Analysts had estimated an EPS of $-0.11.
In a different note, On May 5, 2016, Cowen & Company said it Upgrades its rating on Ariad Pharmaceuticals. The shares have been rated ‘Outperform’ by the firm.
Ariad Pharmaceuticals (ARIA) shares turned negative on Thursdays trading session with the shares closing down -0.02 points or -0.20% at a volume of 43,15,996. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $10.18. The peak price level was also seen at $10.18 while the days lowest was $9.79. Finally the shares closed at $9.91. The 52-week high of the shares is $10.18 while the 52-week low is $4.37. According to the latest information available, the market cap of the company is $1,895 M.
Several Insider Transactions has been reported to the SEC. On Jul 25, 2016, Timothy P Clackson (President, R&D, CSO) sold 18,286 shares at $8.11 per share price.Also, On Jun 29, 2016, Hugh M Cole (SVP, Chief Business Officer) sold 6,012 shares at $7.05 per share price.On Jun 15, 2016, Athanese Lavidas (director) sold 76,250 shares at $8.20 per share price, according to the Form-4 filing with the securities and exchange commission.
ARIAD Pharmaceuticals Inc. is a global oncology company. The Company is engaged in the discovery development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib) brigatinib (AP26113) AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI) which is approved in the United States Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788 is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).